Search Results
Your search for ,led matches 5952 pages
Showing 51 - 100ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
As reported in the Journal of Clinical Oncology by Tung et al, findings in expansion cohorts of the phase II Translational Breast Cancer Research Consortium (TBCRC) 048 study showed that olaparib was active in patients with metastatic breast cancer with germline PALB2 mutations (gPALB2m) and in...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology. The study is a...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer
The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...
Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer?
Color vision deficiency is an inherited condition affecting 1 in 12 males (8%) and 1 in 200 females (0.5%), most often impairing the ability to distinguish the color red. A recent study published in Nature Health examined the possible impact of color vision deficiency on survival outcomes among...
Associations Found Between Air Pollutants and Lung Cancer Subtypes
Both particulate and gaseous air pollutants were linked with subtypes of lung cancer, according to a study published by Diver et al in Environmental Pollution. The analysis, led by investigators from the Barcelona Institute for Global Health (ISGlobal) and the American Cancer Society, showed that...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years old. Born in...
Novel HER2-Targeted Bispecific Improves Outcomes in Patients With Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
New ASCO Guideline Addresses Management of Cancer During Pregnancy, From Diagnosis Through Survivorship
A new ASCO guideline provides recommendations on managing cancer during pregnancy, addressing a range of topics from the selection and timing of diagnostic testing and therapeutic interventions to delivery planning and ethical and legal considerations.1 The guideline aims to inform evidence-based...
Meningiomas: Phase II Trial Shows Activity of Targeted Therapy
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that the CDK 4/6 inhibitor abemaciclib may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. The primary analysis of Alliance A071401 was published by Priscilla...
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In a phase III trial (BRUIN CLL-314) reported in the Journal of Clinical Oncology, Woyach et al found that pirtobrutinib was associated with a noninferior objective response rate vs ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, while also being associated with...
Refractory LBCL: CD19-Targeting CAR T-Cell Therapy Plus Rituximab
A dual-antigen targeting combination of the CD19-targeting chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel plus the CD20-targeting agent rituximab led to durable responses and reduced relapses in patients with refractory large B-cell lymphoma (LBCL), according to findings...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
A novel prostate-specific membrane antigen (PSMA)-targeted radioligand therapy shows the potential to enhance therapeutic effects for patients with PSMA-positive prostate cancer while eliminating the potential for severe adverse effects such as xerostomia, according to preclinical findings...
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by Harter et al, the final results of a European phase III trial (AGO-OVAR 2.29/ENGOT-ov34) showed no significant overall or progression-free survival benefit with the addition of atezolizumab to bevacizumab and nonplatinum chemotherapy in patients...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
As reported in The Lancet by Falchi et al, an interim analysis of the phase III EPCORE FL-1 trial has shown that the addition of the bispecific antibody epcoritamab (for B-cell CD20 and T-cell CD3 antigens) to lenalidomide plus rituximab improved the objective response rate and progression-free...
Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
The combination regimen of FOLFOX chemotherapy (leucovorin, fluorouracil, and oxaliplatin), bevacizumab, and atezolizumab led to a statistically significant improvement in progression-free survival compared with atezolizumab monotherapy for the first-line treatment of patients with deficient...
Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
In a phase III trial (inMIND) reported in The Lancet, Sehn et al found that the addition of the CD19-targeted Fc-enhanced monoclonal antibody tafasitamab to lenalidomide plus rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma. Study Details In...
A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus
Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 By analyzing...
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Researchers have uncovered that sex-specific dysregulation of exosomal non-coding RNAs may drive different patterns of disease progression of multiple myeloma in male and female individuals, according to findings published in Blood Cancer Journal. “The same therapies are provided for men and women ...
CD123-Targeting ADC Shows Activity in AML and BPDCN
Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. In a phase Ib/II trial led by Naval Daver, MD,...
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
As reported in the Journal of Clinical Oncology by Tomasini et al, findings in a cohort of the early-phase CHRYSALIS-2 trial indicate activity of amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC). Study Details In the international trial, ...
Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
The flipped dose for nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of the immunotherapy combination in patients with advanced unresectable melanoma, according to...
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
The addition of the investigational monoclonal antibody ianalumab to eltrombopag extended the time to treatment failure in patients with primary immune thrombocytopenia (ITP) after prior treatment with corticosteroids, according to findings from the phase III VAYHIT2 trial presented at the 2025...
CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were...
Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy–Refractory Advanced Breast Cancers
Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti–PD-1 Therapy in Early Breast Cancer
Preoperative radiation therapy added to anti–PD-1 immune checkpoint inhibition led to a significant increase in T-cell infiltration in patients with hormone receptor–positive/HER2-negative early-stage breast cancer, according to findings from the phase II P-RAD trial presented at the 2025 San...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
Gemcitabine/Nab-Paclitaxel vs Modified FOLFIRINOX in Metastatic Pancreatic Cancer
Similar progression-free survival was found with gemcitabine/nab-paclitaxel vs modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), but less toxicity, according to findings from the...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma
When epcoritamab was added to lenalidomide and rituximab, response rates were significantly higher and progression-free survival was prolonged for patients with follicular lymphoma treated in the second-line setting or beyond, according to findings from the phase III EPCORE FL-1 trial presented at...
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The combination of azacitidine and venetoclax led to improved efficacy outcomes with fewer complications than standard intensive induction chemotherapy as upfront treatment for patients with acute myeloid leukemia (AML), according to trial findings presented at the 2025 American Society of...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding from National Cancer Institute
The Mount Sinai Tisch Cancer Center (TCC) has been named a Comprehensive Cancer Center by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and...
Rainer Storb, MD, Receives Distinguished Wallace H. Coulter Award at ASH Annual Congress
The American Society of Hematology (ASH) presented the Wallace H. Coulter Award for Lifetime Achievement in Hematology to Rainer Storb, MD, during the Society’s Annual Congress held in Orlando. Dr. Storb is Professor Emeritus, Clinical Research Division, at Fred Hutch in Seattle. First awarded in...
One in Three Families of Children With ALL Face Financial Hardship During Treatment
A new multicenter study reports that nearly one-third of families with children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) develop substantial financial hardships during the 2 years of treatment. These difficulties—defined as the inability to pay for housing, food, or utilities, ...
Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved sevabertinib, an oral targeted therapy, for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a...
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
Measurable residual disease (MRD), regardless of the method of assessment, is a robust individual-level predictor for overall survival among patients with acute myeloid leukemia (AML) who have already received induction therapy, according to findings from a pooled analysis presented at the 2025...
ASTRO Marks Former President Biden’s Prostate Cancer Treatment Milestone
The American Society for Radiation Oncology (ASTRO) congratulates former President Joe Biden on completing his course of radiation therapy, which he marked by ringing the ceremonial bell alongside his radiation oncology care team. “President Biden’s bell-ringing milestone underscores the vital role ...
